Efficacy and safety of first-line biological DMARDs in rheumatoid arthritis patients with chronic kidney disease
Authors' conclusion
bDMARDs demonstrated effective and safe profiles in patients with RA with CKD, even among patients on HD. In particular, IL-6is had a significantly higher drug retention rate in patients with an eGFR of <30 mL/min/1.73 m2 and fewer discontinuations due to ineffectiveness. IL-6is were more efficacious as monotherapy compared with the other bDMARDs.
Study context
- Population
- Patients with rheumatoid arthritis (RA) prescribed their first biological disease-modifying antirheumatic drugs (bDMARDs) at two hospitals, 2004–2021, including chronic kidney disease (CKD) and haemodialysis
- Participants
- 425 patients
- Exposure
- First-line bDMARDs across kidney function categories
- Outcome
- Drug retention rate
- Follow-up
- 36 months
Methodological detailstwo hospitals
- Two hospitals
Main finding
As reported in the abstract
Observational data: associations, not effects.
Secondary outcomes
36-month drug retention rate, TNFαis
36-month drug retention rate, IL-6is
36-month drug retention rate, CTLA-4Ig
36-month drug retention rate, TNFαis
- Retention of TNFαis significantly lower in estimated glomerular filtration rate (eGFR) <30
Discontinuation due to ineffectiveness, IL-6is in eGFR <30
- IL-6is showed the highest retention rate and the lowest discontinuation rate due to ineffectiveness in this group: HR
- 0.11 (95% CI 0.02 to 0.85, p=0.03)
DAS28-CRP/erythrocyte sedimentation rate (ESR) and prednisolone dosage
- All bDMARDs improved DAS28-CRP/ESR and reduced prednisolone dosage across all groups
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →